Memory cytokine-enhanced natural killer cells show promising results in leukemia patients; data support immunitybio's scaled m-cenk clinical program

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced study results that further demonstrate the potential for use of memory-like cytokine-enriched natural killer (m-cenk) cells for the treatment of cancer. immunitybio has successfully scaled the process of generating over 20 billion m-cenk cells from a single extraction of white blood cells from a donor or patient, and reports promising clinical data supporting the ongoi
IBRX Ratings Summary
IBRX Quant Ranking